Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
Rattachement africain : tw. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Purpose: Immune checkpoint inhibitors are effective therapies for advanced hepatocellular carcinoma (HCC); however, comparisons of the clinical efficacy and safety profile for these drugs are still scarce. Thus, the aims of this study were to investigate the differences in efficacy and safety between nivolumab and pembrolizumab in unresectable HCC patients in a real-world setting. Patients and methods: A total of 115 patients who received treatment with nivolumab (n = 73) or pembrolizumab (n = 42) in combination with or without tyrosine kinase inhibitors was enrolled. Therapeutic response, survival outcomes, and safety profiles were compared among these groups. Multivariate analysis of survival response was performed using Cox proportional hazards regression. Results: Patients treated with pembrolizumab demonstrated a significantly higher objective response rate than those with nivolumab (38.1% vs. 15.1%; odds ratio 4.18, p = 0.005) regardless of the combination strategies. In addition, pembrolizumab performed a better overall survival (OS) than nivolumab, (34.9 vs. 9.5 months; hazard ratio (HR) = 0.39, p = 0.004). In subgroup analysis, pembrolizumab exhibited favorable OS than nivolumab for monotherapy (HR = 0.16, p = 0.001) or combination therapy (HR = 0.33, p = 0.006) as second-line or later-line (HR = 0.19, p = 0.001) therapy and those with (HR = 0.31, p = 0.006) or without (HR = 0.15, p = 0.004) well-compensated liver disease. The incidence of adverse events was comparable for both treatments. Conclusion: Both pembrolizumab and nivolumab had significant effects for HCC therapy, and pembrolizumab had a significant survival benefit as compared with nivolumab.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
- Date Crossref
- 23/10/2022
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Cheng Kung University Hospital Department of Internal Medicine pays non établi dans la noticeÉtablissement de santé
-
National Cheng Kung University pays non établi dans la noticeUniversité ou école supérieure
-
China Medical University Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
An-Nan Hospital pays non établi dans la noticeÉtablissement de santé
-
Chia Nan University of Pharmacy and Science Department of Environmental Resources Management pays non établi dans la noticeUniversité ou école supérieure
-
National Health Research Institutes pays non établi dans la noticeOrganisation à but non lucratif
-
Tainan Municipal Hospital Department of Internal Medicine pays non établi dans la noticeÉtablissement de santé
-
College of Medicine Institute of Clinical Medicine pays non établi dans la noticeUniversité ou école supérieure
-
National Institute of Cancer Research pays non établi dans la noticeStructure de recherche
-
School of Medicine Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
Department of Internal Medicine — National Cheng Kung University Hospital, National Cheng Kung University et Department of Internal Medicine — China Medical University, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.